Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2015 1
2016 1
2017 3
2018 1
2019 2
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.
Sandström T, Rantalaiho V, Yli-Kerttula T, Kautiainen H, Malmi T, Karjalainen A, Uusitalo T, Julkunen H, Kaipiainen-Seppänen O, Paimela L, Puolakka K, Uutela T, Möttönen T, Hannonen P, Leirisalo-Repo M, Laasonen L, Kauppi M; NEO-RACo Study Group. Sandström T, et al. J Rheumatol. 2020 Aug 1;47(8):1160-1164. doi: 10.3899/jrheum.190139. Epub 2019 Nov 15. J Rheumatol. 2020. PMID: 31732558 Clinical Trial.
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group. Leirisalo-Repo M, et al. Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30. Ann Rheum Dis. 2013. PMID: 22753402 Clinical Trial.
Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
Rantalaiho V, Sandström T, Koski J, Hannonen P, Möttönen T, Kaipiainen-Seppänen O, Yli-Kerttula T, Kauppi MJ, Uutela T, Malmi T, Julkunen H, Laasonen L, Kautiainen H, Leirisalo-Repo M; NEO-RACo Study Group. Rantalaiho V, et al. Arthritis Care Res (Hoboken). 2019 Nov;71(11):1450-1458. doi: 10.1002/acr.23782. Arthritis Care Res (Hoboken). 2019. PMID: 30295425 Clinical Trial.
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group. Rantalaiho V, et al. Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1. Ann Rheum Dis. 2014. PMID: 23908187 Clinical Trial.
Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.
Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, Luosujärvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E; NEO-RACo Study Group. Väänänen T, et al. PLoS One. 2017 Aug 25;12(8):e0183294. doi: 10.1371/journal.pone.0183294. eCollection 2017. PLoS One. 2017. PMID: 28841649 Free PMC article. Clinical Trial.
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Kuusalo L, Puolakka K, Kautiainen H, Blåfield H, Eklund KK, Ilva K, Kaipiainen-Seppänen O, Karjalainen A, Korpela M, Valleala H, Leirisalo-Repo M, Rantalaiho V; Neo-RACo Study Group. Kuusalo L, et al. Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31. Scand J Rheumatol. 2015. PMID: 26324784 Clinical Trial.
Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.
Kuusalo LA, Puolakka KT, Kautiainen H, Alasaarela EM, Hannonen PJ, Julkunen HA, Kaipiainen-Seppänen OA, Korpela MM, Möttönen TT, Paimela LH, Peltomaa RL, Yli-Kerttula TK, Leirisalo-Repo M, Rantalaiho VM; NEO-RACo Study Group. Kuusalo LA, et al. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038-1044. Epub 2016 Aug 2. Clin Exp Rheumatol. 2016. PMID: 27494516 Clinical Trial.
Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group. Rantalaiho V, et al. J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1. J Rheumatol. 2014. PMID: 25274892 Clinical Trial.
11 results